Safety and effectiveness of ibutilide in a community hospital

Charles Thomas Taylor, Amy R. Donaldson

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

To determine the safety and effectiveness of ibutilide, we conducted a retrospective study of patients in a community hospital from December 1997-January 2000, reviewing hospital and pharmacy records for 12 inpatients (aged 68 ± 13 yrs) receiving ibutilide for atrial fibrillation or flutter. The cumulative conversion rate with ibutilide 0.012 ± 0.004 mg/kg was 58%. Serious cardiovascular adverse events were documented in six patients; of those patients, five had baseline QTc intervals above 440 msec, two experienced ventricular fibrillation, and four experienced symptomatic bradycardia (range 49-60 beats/minute) requiring medical intervention. The effectiveness of ibutilide was similar to that found in previous studies. However, more complications were seen in this setting where ibutilide was used infrequently and without stringent patient selection criteria or standardized administration protocols. To ensure optimal patient care, institutions should consider implementing guidelines or education strategies to reduce the potential for serious adverse effects associated with improper screening, dosing, and monitoring of patients receiving ibutilide.

Original languageEnglish
Pages (from-to)488-492
Number of pages5
JournalPharmacotherapy
Volume21
Issue number4
DOIs
StatePublished - 1 Jan 2001

Fingerprint

Community Hospital
Safety
Patient Selection
Atrial Flutter
Hospital Records
Physiologic Monitoring
Ventricular Fibrillation
Bradycardia
Atrial Fibrillation
ibutilide
Inpatients
Patient Care
Retrospective Studies
Guidelines
Education

Cite this

Taylor, Charles Thomas ; Donaldson, Amy R. / Safety and effectiveness of ibutilide in a community hospital. In: Pharmacotherapy. 2001 ; Vol. 21, No. 4. pp. 488-492.
@article{6bde37384bc24866963e6806cf49de97,
title = "Safety and effectiveness of ibutilide in a community hospital",
abstract = "To determine the safety and effectiveness of ibutilide, we conducted a retrospective study of patients in a community hospital from December 1997-January 2000, reviewing hospital and pharmacy records for 12 inpatients (aged 68 ± 13 yrs) receiving ibutilide for atrial fibrillation or flutter. The cumulative conversion rate with ibutilide 0.012 ± 0.004 mg/kg was 58{\%}. Serious cardiovascular adverse events were documented in six patients; of those patients, five had baseline QTc intervals above 440 msec, two experienced ventricular fibrillation, and four experienced symptomatic bradycardia (range 49-60 beats/minute) requiring medical intervention. The effectiveness of ibutilide was similar to that found in previous studies. However, more complications were seen in this setting where ibutilide was used infrequently and without stringent patient selection criteria or standardized administration protocols. To ensure optimal patient care, institutions should consider implementing guidelines or education strategies to reduce the potential for serious adverse effects associated with improper screening, dosing, and monitoring of patients receiving ibutilide.",
author = "Taylor, {Charles Thomas} and Donaldson, {Amy R.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1592/phco.21.5.488.34496",
language = "English",
volume = "21",
pages = "488--492",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Wiley-Blackwell",
number = "4",

}

Safety and effectiveness of ibutilide in a community hospital. / Taylor, Charles Thomas; Donaldson, Amy R.

In: Pharmacotherapy, Vol. 21, No. 4, 01.01.2001, p. 488-492.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Safety and effectiveness of ibutilide in a community hospital

AU - Taylor, Charles Thomas

AU - Donaldson, Amy R.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - To determine the safety and effectiveness of ibutilide, we conducted a retrospective study of patients in a community hospital from December 1997-January 2000, reviewing hospital and pharmacy records for 12 inpatients (aged 68 ± 13 yrs) receiving ibutilide for atrial fibrillation or flutter. The cumulative conversion rate with ibutilide 0.012 ± 0.004 mg/kg was 58%. Serious cardiovascular adverse events were documented in six patients; of those patients, five had baseline QTc intervals above 440 msec, two experienced ventricular fibrillation, and four experienced symptomatic bradycardia (range 49-60 beats/minute) requiring medical intervention. The effectiveness of ibutilide was similar to that found in previous studies. However, more complications were seen in this setting where ibutilide was used infrequently and without stringent patient selection criteria or standardized administration protocols. To ensure optimal patient care, institutions should consider implementing guidelines or education strategies to reduce the potential for serious adverse effects associated with improper screening, dosing, and monitoring of patients receiving ibutilide.

AB - To determine the safety and effectiveness of ibutilide, we conducted a retrospective study of patients in a community hospital from December 1997-January 2000, reviewing hospital and pharmacy records for 12 inpatients (aged 68 ± 13 yrs) receiving ibutilide for atrial fibrillation or flutter. The cumulative conversion rate with ibutilide 0.012 ± 0.004 mg/kg was 58%. Serious cardiovascular adverse events were documented in six patients; of those patients, five had baseline QTc intervals above 440 msec, two experienced ventricular fibrillation, and four experienced symptomatic bradycardia (range 49-60 beats/minute) requiring medical intervention. The effectiveness of ibutilide was similar to that found in previous studies. However, more complications were seen in this setting where ibutilide was used infrequently and without stringent patient selection criteria or standardized administration protocols. To ensure optimal patient care, institutions should consider implementing guidelines or education strategies to reduce the potential for serious adverse effects associated with improper screening, dosing, and monitoring of patients receiving ibutilide.

UR - http://www.scopus.com/inward/record.url?scp=0035066554&partnerID=8YFLogxK

U2 - 10.1592/phco.21.5.488.34496

DO - 10.1592/phco.21.5.488.34496

M3 - Article

VL - 21

SP - 488

EP - 492

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 4

ER -